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ABSTRACT
t(9;22) Ph translocation is a chromosome abnormality recurrent in human chronic myelogenous 
leukemia (CML) and cases of childhood acute lymphoblastic leukemia (ALL). Ph is a marker of 
adverse prognosis significant with remission more frequent and earlier and lower percentage of 
overall survival. If there are less than 5% blasts in a bone marrow sample, the patient is in "clinical 
remission". In the light of sensitivity current controls molecular (10-6) are an important role 
in therapy, although this depends on the amount of cells analyzed. Our goal is to improve the 
sensitivity by proposing a platforms combination, which allow MRD evaluation with only 10 cells. 
Flow cytometry sorting (multiparameter immunological detection), nano-PCR (RNA isolation and 
RT) and qPCR (diagnostic confirmation). The molecular remission has many more probability 
to be lasting that the cytogenetic remission, both before and after the transplant. We consider 
this technique as an important step forward towards performed diagnosis, monitoring treatment 
responses, and identification of relapse in Leukemia patients.
INTRODUCTION
The first chromosomal abnormality associated with malignant disease was the Philadelphia or 
Ph-chromosome identified in chronic myeloid leukemia (CML) (Nowell & Hungerford, 1960). 
Ph-chromosome basically refers to the translocation of chromosome 22 (22q-) with a section of 
chromosome 9 [t (9, 22) (q34, q11)] (Rowley, 1973). t(9;22) Ph translocation is a chromosome 
abnormality recurrent in human chronic myelogenous leukemia (CML) (Nowell & Hungerford, 
1960) and acute lymphoblastic leukemia (ALL) (Kalwinsky et al, 1985). Ph is a marker of adverse 
prognosis significant with remission more frequent and earlier and lower percentage of overall survival 
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(Hoelzer et al, 1988). The minmal residual disease (MRD) is defined as the small number of cancer 
cells that remain in a patient during or after treatment however clinical and microscopic examinations 
confirm the complete remission (CR) and the patient shows no symptoms of the disease. MRD 
is the major cause of disease relapse, its detection gives important feedback about conventional 
treatment success and helps in selecting therapeutic alternatives. The clinical significance of MRD 
has been investigated in patients with acute leukemias with approximately 1012 malignant cells at 
diagnosis. After therapy with a bone marrow normal microscope (CR cytological or hematologic 
CR), yet hold up to 1010 cancer cells. Flow cytometry is the most commonly used technique for the 
diagnosis of haematological malignancies. This method is widely used but a high level of expertise 
is required to interpret the data when it comes to rare event detection such as MRD. The sensitivity 
for the detection of malignant cells varies according to the type of leukaemia, sensitivities of 1 in 
104 up to 1 in 105 (Hauwel & Matthes, 2014). Relative quantification by real time PCR (qPCR) 
based on detecting a leukaemia-specific messenger RNA (mRNA) sequence is commonly used. That 
needs to compare changes in different samples even though the samples vary in quality or quantity. 
In leukemia sensitivity of 106 cells is possible (Brüggemann et al, 2010) however this method is 
criticized because RNA is a much less stable target for diagnostics and requires careful handling and 
processing (Hauwel & Matthes, 2014). 
In the light of sensitivity current controls molecular are an important role in therapy, although 
this depends on the amount of cells analyzed. Our goal is to improve the sensitivity by proposing 
a platforms combination, which allow MRD evaluation with only 10 cells. Flow cytometry sorting 
(multiparameter immunological detection), nano-PCR (RNA isolation and RT) and qPCR 
(diagnostic confirmation). This fast protocol greatly reduces the user error. Samples volume from 
microliters until milliliters allows omits relative quantification, therefore neither calibration curves 
nor constitutive gen quantification. The molecular remission has many more probability to be lasting 
that the cytogenetic remission, both before and after the transplant. We consider this technique 
as an important step forward towards performed diagnosis, monitoring treatment responses, and 
identification of relapse in Leukemia patients.
MATERIAL AND METHODS
Samples: control K562 cell line and blood samples was provided by laboratory CINVESTAV 
(Mexico City, Mexico). 
Multiparameter Flow cytometry: Flow cytometry is based on identifying cell surface antigen 
expression using ﬂuorescence-labeled antibodies. A antibody combination was used to distinguish 
myeloid cells (CD45/CD15 /CD14/CD33 /CD11b) in peripheral blood using MoFlo XDP High-
performance cell sorter (Beckman). 10 positives live cells from each sample were sorted directly onto 
each of the 48 AmpliGrid (Beckman Coulter) reaction sites. 
Nucleic acids extraction: After transferring 0.75 μl of cell extraction working solution (Beckman 
Coulter Cell Extraction Kit) to each reaction site on the AmpliGrid slide, every droplet was covered 
with 5 μl of sealing solution. The loaded AmpliGrid was placed on the AmpliSpeed slide cycler and 
the cell extraction program (5’ 75oC; 2´95oC) was started. 
cDNA synthesis: Nucleic acids (0.75 μL, corresponding to cell extraction volume from 10 
cells) was transcribed into cDNA following a LightCycler t(9;22) Quantification Kit TM (Roche) 
protocol using random hexamer priming and AMV reverse transcriptase. 0.75 μL of RT reaction 
44
mix was added, in the same composition and components proportion recommended for the kit. 
Discard residual cell components for extraction is no necessary. RT conditions 60’ 37o, 10’ 65o and 
final volume of reaction 1.5μl in AmpliSpeed slide cycler.  After cDNA synthesis all samples was 
recovered in 10 μl final volume, 5 μl of the cDNA was used for each of the specific PCRs t(9;22) 
detection and G6PDH detection.
qPCR: Primers and probes: BCR-ABL (BCR-gene, chromosome 22, ABL-gene chromosome 9) 
breakpoints are most mapped to the major (M-bcr) and minor (m-bcr) breakpoint cluster regions. 
Three BCR-ABL breakpoints (b2a2, b3a2 [M-bcr] and e1a2 [m-bcr]) represent about 96 % of 
the described in CML. Those breakpoints are detectable using LightCycler t(9;22) Quantification 
Kit (fig. 1). qPCR in relative quantification (target/reference ratio), normalization, calibrator 
and reference gene are no necessary requisites for this protocol coupled to multiparameter flow 
cytometry and low volume RT. Qualitative real time PCR procedure for BCR-ABL and G6PD 
mRNA transcripts were performed in duplicates using LightCycler t(9;22) Quantification Kit and 
the LightCycler 2.0 (Roche) (fig. 5). RNA control from the kit (originally calibrator) was used only 
like positive control for BCR-ABL and G6PD. PCR amplification was performed according to 
manufacturer’s instruction.
Figure 1. Location of amplification primers and Hybridi-zation Probes for detection of b2a2, b3a2, and e1a2 
transcripts.
RESULTS
Multiparameter Flow cytometry 
Residual AML panel was used like monitor based in residual AML blasts on pre-treatment 
phenotype. Markers Included: CD11b, CD11c, CD13, CD14, CD15, CD33, CD79a and MPOx. 
Figure 2 A shows the analysis of immunophenotype for chronic myeloid leukemia. Figure 2 B 
shows Myeloid cell panel CD45/CD3/CD79a, Myeloperoxidase in blue The phenotype expensively 
defined for chronic myeloid leukemia in blue CD45 with CD33+ CD 15 positive and positive 
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(A). Myeloid cell panel CD45/CD15 /CD14/CD33 /CD11b
(B). Myeloid cell panel CD45/CD3/CD79a, Myeloperoxidase in blue 
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MPOx . 10 blood cell was sorted  directly lo AmpliGril, from subsequent qPCR.
REAL TIME PCR WITH 10 CELLS 
The RNA extracted from the cells 10 were subsequently retro-transcribed and separated to two 
capillaries in amount equivalent of 5 cells. One capillary of each pair contained probes for amplify 
G6PDH and the other probes for amplify t(9;22).
For clarity, the amplification curves for the different capillaries in the experiment are shown in 
different screens. Figure 3 displays the fluorescent signal of the t(9;22) and G6PDH positive control 
kit (capillary 1 and 2 respectively). Negative cell lines for t(9;22) was positive for  G6PDH detection 
and negative for t(9;22) detection (capillary 3 an 4 respetively). Only G6PDH was detected but 
with low efficiency, possibly due to excessive cDNA. Positive cell line has positive signal for G6PDH 
and t(9;22) (capillary 5 and 6 respectively). G6PDH show low efficiency reactions while t(9;22) is 
very clear. No standard curve was included, G6PDH and BCR-ABL concentrations calculus is no 
necessary. NTC for both G6PDH and t(9;22) sowed in capillary 7 and 8.
The results clearly show that qPCR amplification from DNAc extracted the equivalent of 5 cells 
is possible. Even the amount of G6PDH amplification can be so abundant that shows inhibition of 
the reaction. By other hand t(9;22) amplification had ideal DNAc concentration.
Figure 3.  Fluorescent signal of the t(9;22)(capillary 1) and G6PDH positive control kit (capillary 2). Negative cell lines 
for t(9;22) was analyzed  for  G6PDH Detection (capillary  3) and t(9;22) Detection (capillary 4). Positive cell line has 
positive signal for G6PDH and t(9;22) (capillary 5 capillary 6). NTC for both G6PDH and t(9;22) sowed in capillary 
7 and 8.
Melting curves analysis (fig. 4) for the same samples, positives and negatives result was 
confirmed including G6PDH amplification in negative and positive cell control. G6PDH was 
amplified with low efficiency but however t(9;22) in positive samples has very clear signals. Melting 
curves are better analysis method for appreciate a comprehensible result. Melting curves in Fig. 5 
show a DNAc samples set including t(9;22) negative and positive samples. 
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Figure 4.  Detection of BCR-ABL fusion and G6PDH control by melting curves. G6PDH Tm= ±70.5, t(9;22) 
Tm=±70.5. No signal was detected in NTC.
Figure 5:  Melting curves form positives and negatives samples sorted onto AmpliGrid.  Only samples 2 (capillary 2) an 3 
(capillary 4) have positive signal for t(9;22). All samples has positive signal for G6PDH.
CONCLUSIONS
Using Multiparameter Flow cytometry coupled to the low volume cell extraction (AmpliGrid/
Amplispeed technology) and qPCR, a highly sensitive and improved cell analysis can be performed. 
This protocol can enhanced sensitivity analysis especially important in MRD evaluation. Our goal 
is to improve the sensitivity by proposing a platforms combination, which allow Minimal Residual 
Disease evaluation with only 10 cells from samples volume from microliters until milliliters. This 
fast protocol greatly reduces the user error and allows omits relative quantification, therefore neither 
calibration curves nor constitutive gen quantification. 
The molecular remission has many more probability to be lasting that the cytogenetic remission, 
both before and after the transplant. We consider this technique as an important step forward 
towards performed diagnosis, monitoring treatment responses, and identification of relapse in 
Leukemia patients. We present the Here we are the first steps in the development of this protocol In 
order to include it in the options for molecular control evaluation for MRD. 
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